Morgan Stanley downgrades Takeda Pharmaceutical (NYSE:TAK) from Overweight to Equal-Weight.
Wells Fargo Maintains Equal-Weight on NeuroPace, Lowers Price Target to $9
Wells Fargo analyst Lawrence Biegelsen maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and lowers the price target from $11 to $9.